Satipharm CBD Gelpell capsules have 3.5 times higher bioavailability compared to standard CBD oils. This unique product has undergone Stage I and Stage II clinical trials with the results published in two peer-reviewed international medical journals. For further details on the clinical trials, please visit our website; https://www.harvestone.com/portfolio/satipharm/#clinical-trials
VANCOUVER , Nov. 6, 2019 /PRNewswire/ – Harvest One Cannabis Inc. ("Harvest One" or the "Company") (TSX-V: HVT; OTCQX: HRVOF) is pleased to provide an update on its wholly owned subsidiary Satipharm Ltd. ("Satipharm") and its proprietary CBD Gelpell® capsules.
Cautionary Note Regarding Forward-Looking Statements
About Harvest One
Harvest One is also pleased to announce that Satipharm’s CBD Gelpell® capsules are now available in Argentina for medical purposes, and our initial shipment has been received by the first patient. In March 2017 , the Argentine Congress approved a new medical cannabis law. This law authorises the import of cannabis products for sufferers of refractory epilepsy for patients with a doctor’s prescription. Satipharm has signed an agreement with FederalMed to manage the importation and distribution of Satipharm’s CBD Gelpell® capsules to patients.
Harvest One is a global cannabis company that develops and provides innovative health, wellness, and self-care products to consumers and patients in regulated markets around the world. The Company’s range of solutions is designed to enhance quality of life. Shareholders have significant exposure to the entire cannabis value chain through four wholly owned subsidiaries: United Greeneries, a licensed producer; Satipharm (medical and nutraceutical); and Dream Water Global and Delivra (CPG), and a minority interest in Burb Cannabis (retail operations). For more information, please visit www.harvestone.com.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. The forward-looking information contained in this press release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
Please note that when purchasing high unit volumes of single lines (10+ units) that delivery promotions are null and void.
This is as a result of high volume orders not being able to be dispatched via our normal third party fulfilment.
As a result for any excessive bulk orders of single lines we will be in touch regarding your order to discuss further delivery costs that will be incurred.
Pharmacy Medicines will need to be signed for by someone aged 18 or over. If there isn’t anyone in who can sign for your order, you can change your delivery date or redirect it to a local parcel shop using the courier’s website or app.
Developed specifically for optimum bioavailability and consistency.
Satipharm CBD 10mg Gelpell® has been created using full spectrum CBD hemp extract and a patented formulation that delivers 3.5 times the amount of bioavailability. Satipharm CBD capsules are 350% more effective than oils and each Gelpell® capsule delivers a precise dose of CBD. Delivered to you in Satipharm’s patented Gelpell® technology, which places CBD extract in seamless gelatine beads. These beads are then placed in a gastro-resistant capsule, ensuring that the CBD is released in the small intestine in precise doses, improving the effectiveness of each CBD capsule.
Pharmacy Medicines delivery
Gelatine (bovine), full spectrum extract of hemp, water, colour: E141 (copper chlorophyllin).
*Please note: If your chosen pharmacy is in the North West, North East, Yorkshire, the Isle of Man, Channel Islands or Scottish Highlands and Islands your order will take an additional working day to these delivery times. To find out if your pharmacy is impacted click here .
Satipharm products are manufactured under Good Manufacturing Practice (GMP). This ensures the highest quality of safety standards are followed to deliver our CBD Gelpell® capsules. We would not recommend that you use CBD oil with medicines. If you are already using CBD products with prescription medication or other medicines, we recommend speaking to your doctor for advice. If you are pregnant or are breast feeding, we also recommend you consult with your doctor before taking CBD products. CBD oil is not intended to diagnose, treat, cure or prevent any ailments..
Unfortunately, your order can’t be left in a safe place or with a neighbour. The courier will try to deliver three times before they return it to us.
If you’re not completely satisfied with your order, you can return it to us within 28 days
Find out more about our returns policy click here